Last 7 days
-3.6%
Last 30 days
3.0%
Last 90 days
6.8%
Trailing 12 Months
45.2%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
UNH | 448.8B | 335.9B | -0.30% | -2.84% | 21.68 | 1.34 | 12.90% | 18.65% |
MCK | 54.3B | 276.7B | 7.99% | 15.32% | 15.25 | 0.2 | 4.83% | 219.57% |
ABC | 34.1B | 247.5B | 1.76% | 8.76% | 21.08 | 0.14 | 7.78% | -6.37% |
CAH | 21.6B | 198.7B | 3.04% | 45.15% | 46.69 | 0.11 | 12.34% | 148.48% |
HSIC | 9.8B | 12.5B | -7.75% | -12.50% | 20.56 | 0.78 | -1.00% | -26.01% |
MID-CAP | ||||||||
LHCG | 5.2B | 2.3B | 3.17% | 35.63% | 86.23 | 2.28 | 2.85% | -58.05% |
HQY | 4.7B | 861.7M | 2.36% | -9.64% | -178.64 | 5.42 | 13.90% | 40.97% |
AMN | 3.9B | 4.8B | 11.84% | 2.65% | 10.12 | 0.8 | 3.57% | -4.88% |
PDCO | 2.6B | 6.4B | 0.49% | -14.18% | 13.26 | 0.41 | -0.52% | 16.73% |
SMALL-CAP | ||||||||
RDNT | 1.7B | 1.5B | 6.01% | 44.82% | -126.07 | 1.14 | 10.24% | -173.11% |
OMI | 1.6B | 10.0B | 39.29% | -41.00% | 69.33 | 0.16 | 1.74% | -89.90% |
ADUS | 1.4B | 976.1M | -21.09% | 3.91% | 28.65 | 1.47 | 10.19% | 12.37% |
BKD | 645.6M | 2.9B | -18.53% | -39.08% | -3.53 | 0.22 | 7.97% | -101.02% |
PETQ | 365.7M | 921.5M | 9.46% | -21.33% | -8.78 | 0.4 | -1.18% | -180.05% |
SMED | 170.0M | - | 1.98% | -1.24% | 31.24 | 2.46 | - | - |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | 2.9% | 198,662 | 193,011 | 186,999 | 181,364 | 176,847 |
Gross Profit | 1.6% | 6,667 | 6,564 | 6,517 | 6,545 | 6,415 |
S&GA Expenses | 0.9% | 4,722 | 4,680 | 4,640 | 4,557 | 4,531 |
EBITDA | 417.1% | 631 | -199 | 72.00 | 230 | - |
EBITDA Margin | 407.2% | 0.00* | 0.00* | 0.00* | 0.00* | - |
Earnings Before Taxes | 354.7% | 489 | -192 | -1,028 | -769 | -622 |
EBT Margin | 81.9% | 0.00* | -0.01* | 0.00* | 0.00* | - |
Interest Expenses | -8.2% | 112 | 122 | 134 | 149 | 159 |
Net Income | 136.4% | 463 | -1,273 | -1,094 | -933 | -955 |
Net Income Margin | -12.7% | -0.01* | -0.01* | -0.01* | -0.01* | - |
Free Cahsflow | -17.9% | 2,792 | 3,401 | 2,735 | 446 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -2.5% | 43,377 | 44,482 | 43,387 | 43,878 | 42,111 |
Current Assets | -3.2% | 33,497 | 34,596 | 32,696 | 32,935 | 30,884 |
Cash Equivalents | 9.2% | 3,990 | 3,654 | 3,492 | 4,717 | 2,356 |
Inventory | -3.7% | 16,620 | 17,263 | 15,891 | 15,636 | 15,493 |
Net PPE | 0.9% | 2,362 | 2,341 | 2,339 | 2,361 | 2,298 |
Current Liabilities | -2.1% | 32,503 | 33,212 | 31,559 | 30,550 | 28,715 |
Long Term Debt | 0.5% | 4,708 | 4,685 | 4,689 | 4,735 | 4,751 |
Shareholder's Equity | -0.3% | -2,218 | -2,212 | -706 | -693 | - |
Retained Earnings | 38.9% | -342 | -560 | -301 | -280 | -281 |
Shares Outstanding | -3.7% | 261 | 271 | 275 | - | - |
Minority Interest | 100.0% | 2.00 | 1.00 | 1.00 | 3.00 | 4.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | 55.7% | 4,973 | 3,193 | 3,791 | 3,122 | 795 |
Share Based Compensation | -2.3% | 85.00 | 87.00 | 80.00 | 81.00 | 70.00 |
Cashflow From Investing | -11.6% | -452 | -405 | -365 | 567 | 683 |
Cashflow From Financing | -26.1% | -2,874 | -2,280 | -2,362 | -2,463 | -2,697 |
Dividend Payments | -1.5% | 533 | 541 | 552 | 559 | 566 |
Buy Backs | 3.4% | 1,500 | 1,450 | 1,500 | 1,000 | 1,000 |
65.4%
16.9%
0%
Y-axis is the maximum loss one would have experienced if Cardinal Health was unfortunately bought at previous high price.
8.7%
4.1%
13.3%
19.9%
FIve years rolling returns for Cardinal Health.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-24 | Old North State Trust, LLC | unchanged | - | - | 10,000 | 0.01% |
2023-05-23 | Toroso Investments, LLC | added | 123 | 1,038,000 | 1,904,000 | 0.03% |
2023-05-23 | Brookfield Corp /ON/ | new | - | 4,100,180 | 4,100,180 | 0.02% |
2023-05-23 | Front Row Advisors LLC | added | - | 3,000 | 3,000 | -% |
2023-05-22 | BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL | unchanged | - | -11,029 | 607,775 | 0.24% |
2023-05-22 | PUTNAM INVESTMENTS LLC | added | 3.77 | 117,887 | 6,254,500 | 0.01% |
2023-05-22 | FDx Advisors, Inc. | unchanged | - | - | 424,000 | 0.02% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -4.88 | -7,318,580 | 103,286,000 | 0.03% |
2023-05-19 | Coppell Advisory Solutions LLC | sold off | -100 | -7,687 | - | -% |
2023-05-18 | OLD REPUBLIC INTERNATIONAL CORP | unchanged | - | -1,159,000 | 63,873,000 | 2.04% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | price t rowe associates inc /md/ | 1.9% | 4,994,087 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 11.95% | 31,320,204 | SC 13G/A | |
Feb 06, 2023 | state street corp | 6.70% | 17,568,683 | SC 13G/A | |
Jan 26, 2023 | blackrock inc. | 11.3% | 29,572,939 | SC 13G/A | |
Jan 20, 2023 | blackrock inc. | 11.3% | 29,572,939 | SC 13G/A | |
Sep 08, 2022 | blackrock inc. | 10.6% | 28,946,151 | SC 13G | |
Feb 14, 2022 | price t rowe associates inc /md/ | 5.3% | 15,028,767 | SC 13G | |
Feb 10, 2022 | state street corp | 7.59% | 21,384,169 | SC 13G/A | |
Feb 09, 2022 | vanguard group inc | 12.72% | 35,841,618 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 7.8% | 21,999,306 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 87.64 5.81% | 137.55 66.06% | 253.05 205.51% | 406.67 390.97% | 579.72 599.89% |
Current Inflation | 79.79 -3.67% | 123.67 49.31% | 223.04 169.27% | 354.51 328.00% | 502.19 506.29% |
Very High Inflation | 71.22 -14.02% | 108.43 30.91% | 191.37 131.04% | 299.12 261.13% | 419.37 406.30% |
Date Filed | Form Type | Document | |
---|---|---|---|
May 17, 2023 | 4 | Insider Trading | |
May 11, 2023 | 8-K | Current Report | |
May 04, 2023 | 8-K | Current Report | |
May 04, 2023 | 10-Q | Quarterly Report | |
Mar 16, 2023 | 4 | Insider Trading | |
Mar 16, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 8-K | Current Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-15 | Hollar Jason M. | sold (taxes) | -257,446 | 84.77 | -3,037 | chief executive officer |
2023-03-15 | Mayer Jessica L | sold (taxes) | -94,481 | 70.72 | -1,336 | chief legal/compliance officer |
2023-03-15 | Greene Michelle D. | sold (taxes) | -47,311 | 70.72 | -669 | chief information officer |
2023-02-15 | Alt Aaron E | acquired | - | - | 12,726 | chief financial officer |
2022-12-01 | Snow Ola M | sold (taxes) | -47,781 | 80.17 | -596 | chief human resources officer |
2022-12-01 | WEITZMAN DEBORAH | sold (taxes) | -30,464 | 80.17 | -380 | ceo, pharmaceutical segment |
2022-11-15 | Brennan Michelle | bought | 14,944 | 74.72 | 200 | - |
2022-11-15 | Mayer Jessica L | sold (taxes) | -389,964 | 75.21 | -5,185 | chief legal/compliance officer |
2022-11-14 | Brennan Michelle | bought | 15,260 | 76.3 | 200 | - |
2022-11-10 | Brennan Michelle | bought | 11,961 | 79.74 | 150 | - |
Condensed Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Income Statement [Abstract] | ||||
Revenue | $ 50,487 | $ 44,836 | $ 151,559 | $ 134,261 |
Cost of products sold | 48,702 | 43,154 | 146,497 | 129,321 |
Gross margin | 1,785 | 1,682 | 5,062 | 4,940 |
Operating expenses: | ||||
Distribution, selling, general and administrative expenses | 1,179 | 1,137 | 3,567 | 3,402 |
Restructuring and employee severance | 16 | 31 | 62 | 56 |
Amortization and other acquisition-related costs | 74 | 79 | 216 | 237 |
Impairments and (gain)/loss on disposal of assets, net | 20 | 471 | 883 | 1,764 |
Litigation (recoveries)/charges, net | (76) | 61 | (256) | 113 |
Operating earnings/(loss) | 572 | (97) | 590 | (632) |
Other (income)/expense, net | 0 | 3 | (5) | (14) |
Interest expense, net | 28 | 38 | 78 | 115 |
Loss on early extinguishment of debt | 0 | 0 | 0 | 10 |
(Gain)/loss on sale of equity interest in naviHealth | 0 | (1) | 0 | (2) |
Earnings/(loss) before income taxes | 544 | (137) | 517 | (741) |
Provision for income taxes | 197 | 1,253 | 189 | 328 |
Net earnings/(loss) | 347 | (1,390) | 328 | (1,069) |
Less: Net earnings attributable to noncontrolling interests | (2) | (1) | (3) | (2) |
Net earnings/(loss) attributable to Cardinal Health, Inc. | $ 345 | $ (1,391) | $ 325 | $ (1,071) |
Earnings/(Loss) per common share attributable to Cardinal Health, Inc.: | ||||
Basic (in shares) | $ 1.35 | $ (5.05) | $ 1.24 | $ (3.82) |
Diluted (in shares) | $ 1.34 | $ (5.05) | $ 1.23 | $ (3.82) |
Weighted-average number of common shares outstanding: | ||||
Basic (in shares) | 256 | 275 | 263 | 281 |
Diluted (in shares) | 258 | 275 | 264 | 281 |
Cash dividends declared per common share | $ 0.4957 | $ 0.4908 | $ 1.4871 | $ 1.4724 |
Condensed Consolidated Balance Sheets - USD ($) shares in Thousands, $ in Millions | Mar. 31, 2023 | Jun. 30, 2022 |
---|---|---|
Current assets: | ||
Cash and equivalents | $ 3,990 | $ 4,717 |
Trade receivables, net | 10,992 | 10,561 |
Inventories, net | 16,620 | 15,636 |
Prepaid expenses and other | 1,895 | 2,021 |
Total current assets | 33,497 | 32,935 |
Property and equipment, net | 2,362 | 2,361 |
Goodwill and other intangibles, net | 6,567 | 7,629 |
Other assets | 951 | 953 |
Total assets | 43,377 | 43,878 |
Current liabilities: | ||
Accounts payable | 29,601 | 27,128 |
Current portion of long-term obligations and other short-term borrowings | 26 | 580 |
Other accrued liabilities | 2,876 | 2,842 |
Total current liabilities | 32,503 | 30,550 |
Long-term obligations, less current portion | 4,708 | 4,735 |
Deferred income taxes and other liabilities | 8,384 | 9,299 |
Preferred shares, without par value: | ||
Authorized—500 thousand shares, Issued—none | 0 | 0 |
Common shares, without par value: | ||
Authorized—755 million shares, Issued—327 million shares at March 31, 2023 and June 30, 2022 | 2,818 | 2,813 |
Accumulated deficit | (342) | (280) |
Common shares in treasury, at cost: 72 million shares and 54 million shares at March 31, 2023 and June 30, 2022, respectively | (4,554) | (3,128) |
Accumulated other comprehensive loss | (142) | (114) |
Total Cardinal Health, Inc. shareholders' deficit | (2,220) | (709) |
Noncontrolling interests | 2 | 3 |
Total shareholders’ deficit | (2,218) | (706) |
Total liabilities and shareholders’ deficit | $ 43,377 | $ 43,878 |
Preferred shares, authorized | 500 | 500 |
Preferred shares, issued | 0 | 0 |
Common shares, authorized | 755,000 | 755,000 |
Common shares, issued | 327,000 | 327,000 |
Common shares in treasury | 72,000 | 54,000 |